The findings were part of the Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) Study, an ongoing prevention trial with a primary objective of probing normal older adults with increased brain amyloid.
Researchers turn to a beta-amyloid antagonist for hope in treating Alzheimer's.